posted
its a slow runner, but stable. just a heads up. glassman also has a topic in hotstocks for it
Posts: 2329 | From: MD | Registered: Jul 2005
| IP: Logged |
posted
Ellipsis Biotherapeutics Completes Four Contracts for High Through-Put Genotyping Services PrimeZone SARASOTA, Fla., Feb. 21, 2006 (PRIMEZONE) -- DNAPrint Genomics, Inc. (OTCBB:DNAG) today announced that Ellipsis Biotherapeutics, Inc. will complete a record quarter of revenue generation from high volume SNP genotyping. A significant portion of the revenue came from four contracts, including a major American university, two United Kingdom academic research groups, and one Toronto based academic hospital program. Ellipsis, acquired by the Company in November 2005, conducts SNP genotyping using state-of-the-art technologies. These include single-base primer extension platforms from Beckman Coulter, Inc. and the GoldenGate(tm) platform from Illumina, Inc. With a choice of platforms and scales for performing work, Ellipsis supports companies through the entire scope of their genotyping efforts. Projects include both high throughput screening of multiple samples as well as finer mapping to clarify associations of genetic predisposition in a variety of human diseases.
"Our goal is to deliver the highest quality SNP genotyping services to the marketplace, including project development, ongoing scientific advice and data analysis and interpretation," commented Dr. Laurence Rubin, founder of Ellipsis. "Ellipsis has completed these projects on schedule and within budget. Our services have been instrumental in helping scientists publish their work in respected scientific journals. In addition to completing large volume contract services for a variety of projects, we are participating in novel research programs, which has always been part of the company's focus," he added.
"We are extremely pleased that Ellipsis Biotherapeutics has met its first major milestone and has done it with better than budgeted goals and objectives. We expect that Ellipsis will continue to contribute to our revenue growth and assist our core pursuit of pharmaceuticals and diagnostics," said Richard Gabriel, Chief Executive Officer and President of DNAPrint Genomics, Inc
Posts: 529 | From: CA | Registered: Jan 2005
| IP: Logged |
posted
DNAG is now rated a 96% BUY on Barcharts.com
80% Short Term Buy 100% Medium Term Buy 100% Long Term Buy
This still seems to be flying under the radar on this board, although volume has been high the past couple weeks.
As I said earlier, I have rode this one for 100% in the past and sold off. I'm now back in at .023 and looking for 80% or more this time.
Posts: 119 | From: Attleboro,MA USA | Registered: Nov 2004
| IP: Logged |
DNAPrint Genomics Ancestry Test Broadens Perspective on Family Heritage for CBS Early Show Co-Anchor Market Wire
SARASOTA, FL -- (MARKET WIRE) -- 02/23/06 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that during a CBS Early Show broadcast, co-anchor Rene Syler described how the Company's ANCESTRYbyDNA(TM) test assisted her in determining her family's bio-geographical ancestry.
Syler was joined by her mother in an Early Show segment on Wednesday, February 22, for a discussion about their efforts to learn more about the family's past through DNA testing. Although her family's roots stretched back to Africa, Syler said she wanted to know more about her background in order to teach her children that their history does not begin with slavery.
After taking a basic mitochondrial DNA test, Syler learned that her maternal genetic ancestry included Irish, British or Scandinavian blood. These results piqued Syler's curiosity, because her mother had told her that the family had Native American lineage. Syler then turned to DNAPrint's ANCESTRYbyDNA test, which determined that her makeup was 59 percent sub-Saharan African, 25 percent European, 14 percent Native American, and 2 percent East Asian.
Syler described her reaction to the news as "blown away."
With ancestry, appearances can be deceiving. Anne Syler, the anchor's mother, said she only had a vague idea about their ancestry. "In fact, I was accepted as either French, Indian or Italian even, or Spanish," she said. "People have thought of me as all kinds of races."
DNAPrint Genomics offers a variety of tests for people interested in exploring their family heritage, including African Ancestry mtDNA test. In addition to ANCESTRYbyDNA, the Company's EURO-DNA(TM) test makes it possible for individuals of European descent to discover their hereditary profile in greater detail. ANCESTRY-MITO traces family origin along the maternal line while ANCESTRY-Y for men traces a paternal line. Ancestry kits offered by the Company come with a mouth swab that is sent back to DNAPrint's laboratory, analyzed, and the results, including genealogical history, are returned on a CD-ROM disc. The basic ANCESTRYbyDNA kit retails for $219.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company for additional forensics work. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results. The Company also performs contract genotyping and other DNA services through its Ellipsis Biotherapeutics group in Toronto, Canada.
-------------------- Veni Vidi Vici Posts: 529 | From: CA | Registered: Jan 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
